MTAP and melanoma: In line with this notion, recent studies have described a worse response of 9p21/MTAP‐deficient melanoma, non‐small cell lung cancer, and metastatic urothelial cancer to CPIs as compared to 9p21/MTAP‐proficient cancers [16, 88, 89].